Equity Overview
Price & Market Data
Price: $11.78
Daily Change: -$0.29 / 2.46%
Daily Range: $11.67 - $12.09
Market Cap: $1,209,517,440
Daily Volume: 1,367,669
Performance Metrics
1 Week: 7.09%
1 Month: -2.40%
3 Months: 37.46%
6 Months: 72.98%
1 Year: -3.68%
YTD: 26.39%
Company Details
Employees: 181
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.